How Often Do Pacemaker Leads Need to Be Replaced?

Most pacemaker leads last well beyond a decade in practice, but when they do fail, the median time to failure sits around seven years, with wide variation depending on the lead’s design, insulation material, and the patient’s anatomy. That number comes from a large multicenter study tracking leads over eight years, though many individual leads function reliably for 15 or even 20 years before any trouble appears. The question of “how often” leads need replacement is less about a fixed schedule and more about understanding what eventually goes wrong, how doctors detect it, and what the options look like when a lead stops working properly.

What Causes Leads to Fail

Pacemaker leads are thin, flexible wires threaded through veins and anchored inside the heart. They carry electrical impulses from the pulse generator to the heart muscle, and they relay the heart’s own signals back to the device. Given what they endure, the fact that they last as long as they do is remarkable. Every heartbeat flexes them slightly, and every arm and shoulder movement tugs on them where they pass through the space between the collarbone and the first rib.

In a large prospective study following over 3,000 patients, insulation defects were the leading cause of lead failure, and most of the leads that failed this way used polyurethane insulation materials. The median time to failure was about seven years, though the spread was wide. Lead failure in that study was associated with a 16% rate of major adverse clinical events, meaning that a failing lead isn’t just an inconvenience but a genuine medical problem.¹

Insulation breakdown happens because the outer coating of the lead gradually degrades. Polyurethane, once common, turned out to be vulnerable to cracking over time inside the body. Silicone-based insulation has proven more durable in many designs, though it comes with its own trade-offs like being slightly thicker and less slippery during implantation. In some cases, insulation damage occurs at pinch points where the lead gets compressed between the collarbone and the underlying rib, a mechanism sometimes called “subclavian crush.” One case report described a lead failing more than three years after implantation because it was being repeatedly pinched by the musculotendinous structures near the collarbone during arm movement.²

Lead fracture, where the internal conductor wire actually breaks, is the other major failure mode. This can happen from mechanical stress at the same pinch points, or from repeated bending at the spot where the lead enters the vein. A fracture can cause intermittent or complete loss of pacing, and it sometimes shows up as erratic signals on routine device checks before the patient feels anything.

How Lead Design Affects Longevity

Leads are anchored inside the heart in one of two ways. Active-fixation leads have a tiny screw at the tip that threads into the heart muscle. Passive-fixation leads use small tines or fins that lodge in the heart’s trabecular tissue, the irregular ridges lining the inner walls of the ventricle. Each design has different implications for long-term performance.

A five-year prospective study comparing the two types found that both performed reliably over the study period, with no significant difference in electrical performance by the end. Active-fixation leads started with slightly higher pacing thresholds that dropped over the first month, while passive-fixation leads started lower but crept up slightly over time. By five years, the two types had converged. Each type had a small number of adverse events: one active lead dislodged, and one passive lead developed an insulation fracture.³

Where the difference becomes more meaningful is in cardiac resynchronization therapy, where a lead is placed in the left ventricle through the coronary sinus. A study comparing active-fixation quadripolar leads to passive-fixation quadripolar leads in that setting found that the active-fixation group had roughly half the rate of lead-related complications. Lead dislodgement occurred only in the passive-fixation group, and the active-fixation group showed a hazard ratio of 0.44 for complications overall.⁴ This matters because every lead replacement carries its own risks, so a design that reduces the chance of early dislodgement effectively extends the usable life of the system.

Why Leads Fail Sooner in Children

The seven-year median from adult studies doesn’t translate directly to younger patients. Children and adolescents who need pacemakers face a fundamentally different problem: they are still growing. A lead implanted in a five-year-old has to keep working as that child’s body gets taller, their chest expands, and their heart changes size.

A recent study found that the single strongest predictor of lead failure in pediatric and congenital heart disease patients was somatic growth of five centimeters per year or more, which carried a hazard ratio of 3.33 for lead failure. Male sex, younger age at implant, and epicardial lead placement also increased risk.⁵ An earlier study confirmed that children under 12 at the time of implant experienced significantly more lead fractures, and those with structural congenital heart defects had more problems with rising pacing thresholds, a sign that the lead tip is losing good contact with the heart muscle.⁶

This means a child who receives a pacemaker may go through multiple lead replacements over a lifetime, a reality that shapes how cardiologists approach lead management from the very first implant. Every additional lead in the venous system makes future procedures harder, which is why the pediatric population stands to benefit most from newer leadless technologies.

What Happens When a Lead Stops Working

When a lead fails or is no longer needed, the doctor faces a decision: extract the old lead or leave it in place and add a new one alongside it. Both strategies are common, and neither is universally better. The choice depends on the patient’s age, the reason the lead failed, how many leads are already in place, and whether there is enough room in the veins for another wire.

Expert consensus statements acknowledge this tension directly. Removing a lead eliminates unnecessary hardware and can reopen an occluded vein, making it possible to place a new lead through the same access route. Leaving the lead in place avoids the procedural risks of extraction, which increase with the age of the lead and the patient’s overall health.⁷ One review went so far as to state that the only truly necessary indication for lead extraction is infection, and that non-functional leads can generally be more safely abandoned than extracted.⁸

The data on abandoned leads offers some reassurance. A study comparing patients with a single abandoned lead to matched controls found no significant difference in rates of infection, venous thrombosis, or death. However, patients with multiple abandoned leads did face meaningfully higher risks, with a hazard ratio of 8.61 for infection and 2.42 for all-cause mortality compared to controls.⁹ That finding underscores why accumulating leads is a real concern, especially in younger patients who may need many device revisions over a lifetime.

A large national registry comparison found that patients undergoing lead extraction had slightly higher in-hospital complication rates and death rates than those who had leads abandoned. In a Medicare subset followed for one year, there was a trend toward higher mortality in the extraction group, though it did not reach clear statistical significance.¹⁰

The Risks of Lead Extraction

Extracting a lead that has been in place for years is not a simple pull. Over time, the body forms fibrous scar tissue around the lead, essentially welding it to the vein walls and the inside of the heart. A histological study of this tissue found that it consists of a collagen-rich matrix with a large proportion of myofibroblasts, cells that actively contract. This contractile scar tissue is what makes old leads resist removal and explains why extraction forces can sometimes tear delicate vascular or cardiac structures.¹¹

Specialized tools have been developed to deal with this. Extraction sheaths, essentially tubes that slide over the lead and use laser energy, mechanical cutting, or simple dilation to free it from surrounding tissue, have dramatically improved success and safety. But the procedure still carries real risk. A national registry analysis of over 11,000 extraction procedures found major complications in about 2.3% of cases. Of those, roughly one in six required emergency cardiac surgery, and about a third of those surgical patients died. Overall, around 0.9% of extraction patients died, with 0.16% dying during the procedure itself. Predictors of complications included female sex, having three or more leads extracted, longer implant duration, and the presence of infection.¹²

Data from a high-volume extraction center using mechanical-only tools reported a 3.2% major complication rate and a 0.6% procedural mortality rate, alongside a 10% minor complication rate.¹³ These numbers may sound small in percentage terms, but they are not trivial for an elective procedure, which is part of why doctors weigh the decision so carefully.

Infection and Mandatory Lead Removal

While a malfunctioning but uninfected lead can sometimes be safely abandoned, infection changes the calculus entirely. An infected pacemaker system almost always requires complete removal of all hardware, including every lead and the pulse generator. Leaving infected material in place allows bacteria to persist on the device surfaces, where they form protective biofilms that antibiotics alone cannot penetrate.

Device-related infection rates vary by device complexity. The incidence has been reported at around 1.7% within six months for implantable defibrillators and as high as 9.5% within two years for cardiac resynchronization devices, which involve more leads and longer procedures.¹⁴ Staphylococcal species dominate. In one series of 189 patients with confirmed device infections, coagulase-negative staphylococci accounted for 42% of cases and Staphylococcus aureus for 29%. Complete device removal combined with antibiotics cured 96% of those patients.¹⁵

When infection reaches the leads inside the heart (a condition called lead endocarditis), the stakes rise sharply. A study of 52 patients with pacemaker-lead endocarditis found fever in nearly 87%, pulmonary involvement in about 38%, and an overall mortality of nearly 27% over a follow-up period averaging 20 months. The germ was identified in about 88% of patients, and staphylococcal species accounted for the vast majority.¹⁶ These outcomes make the case for swift action when infection is suspected.

Economic modeling from the UK has reinforced this point. A cost-effectiveness analysis found that early extraction for infected devices resulted in fewer adverse events, lower mortality, and lower total costs compared to delayed or no extraction. Over a one-year horizon, early extraction saved roughly £123,000 per 100 patients while reducing mortality from 20 per 100 patients to about 8 per 100 patients.¹⁷

Venous Occlusion and the Crowding Problem

Even when leads function perfectly, their presence gradually affects the veins they pass through. Scar tissue and clot formation can narrow or completely block the subclavian vein, the main vessel used for lead insertion. A study of 212 consecutive patients with previously implanted leads found total occlusion of the subclavian or innominate vein in about 26%.¹⁸ This narrowing or blockage is often clinically silent, meaning the patient has no symptoms, but it becomes a significant obstacle when a new lead needs to be placed.

Vein stenosis or occlusion is common enough that cardiologists have developed specialized techniques to work around it, including venoplasty (balloon dilation of the narrowed vein), placement through alternative veins, or tunneling new leads from the opposite side of the chest.¹⁹ This is one of the practical reasons why extracting old leads rather than abandoning them can make sense, especially in patients likely to need future procedures: removing the old lead and its surrounding scar can reopen the vein for a replacement.

Recalled Leads and Manufacturing Variability

Not all lead failures are caused by normal wear. Some leads have been recalled due to design or manufacturing flaws that caused them to fail at unacceptably high rates. The two most prominent recalls involved the Medtronic Sprint Fidelis leads, recalled in 2007, and the St. Jude Medical Riata and Riata ST leads, recalled in 2011. A study analyzing failure patterns found that recalled leads failed predominantly by fracture: 89% of Sprint Fidelis failures and 65% of Riata/Riata ST failures presented as fractures. There was a strong correlation between recalled lead status and both lead failure and patient mortality.²⁰

Even among non-recalled leads, fracture was the most common failure mode, accounting for about 51% of failures in the same study. The manufacturer and specific lead model matter. Some lead designs have proven remarkably durable across decades, while others have developed reputations for earlier-than-expected failures. If you have a pacemaker, knowing the specific model of your leads (listed on your device identification card) lets your cardiologist check whether any advisories or recalls apply.

Leadless Pacemakers and the Future of the Problem

The vulnerabilities of transvenous leads have driven development of an entirely different approach: leadless pacemakers. These are self-contained capsules, roughly the size of a large vitamin pill, implanted directly into the right ventricle through a catheter inserted in the leg. They contain the battery, electronics, and electrode all in one unit, eliminating the lead entirely.

A review in the European Cardiology Review described transvenous leads as the “Achilles’ heel” of pacing therapy and noted that advances in battery technology and miniaturized electronics now make it possible to implant the entire pacemaker system inside the heart chamber.²¹ A retrospective comparison of leadless and conventional pacemakers found that conventional systems had significantly higher rates of electrode dislodgement, pocket site infection, and lead fracture. Leadless devices showed lower infection rates and no lead fracture at all, for the obvious reason that there is no lead to fracture.²²

Leadless pacemakers do have their own limitations. Current models can only pace one chamber of the heart, which is not suitable for every patient. When the battery runs out, the depleted device is typically left in place and a new one is implanted alongside it, raising questions about what happens when a patient accumulates multiple capsules inside the right ventricle over a lifetime. And while rates of pericardial effusion, hematoma, and thrombosis were similar between leadless and conventional pacemakers in the retrospective comparison, the technology is still young enough that very long-term data beyond 10 to 15 years remain sparse. For patients who need only single-chamber ventricular pacing, though, leadless devices effectively sidestep the lead replacement question altogether.